Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 12/20 | 0.58 |
| ▸ | CNR1 | P21554 | 5/20 | 0.58 |
| ▸ | CRACR2A | Q9BSW2 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MARS1 | P56192 | 1/20 | 0.36 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4929203 | 1.00 | CNR2 (0.58) | CNR2CNR1CRACR2AKMT2AMARS1 | |
| SCHEMBL4934269 | 1.00 | CNR2 (0.58) | CNR2CNR1CRACR2AKMT2AMARS1 | |
| SCHEMBL1431958 | 0.88 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL4931402 | 0.88 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL4934195 | 0.88 | CNR2 (0.72) | CNR2CNR1 | |
| SCHEMBL1431791 | 0.88 | CNR2 (0.47) | CNR2CNR1MARS1 | |
| SCHEMBL4925586 | 0.84 | CNR2 (0.54) | CNR2CNR1 | |
| SCHEMBL4933151 | 0.84 | CNR2 (0.82) | CNR2CNR1 | |
| SCHEMBL3850298 | 0.84 | CNR2 (0.82) | CNR2CNR1 | |
| SCHEMBL4934081 | 0.84 | CNR2 (0.82) | CNR2CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | GLENMARK PHARMACEUTICALS S.A. (CH) | 2008-08-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200501-A1 | NOVEL CANNABINOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION | CNR2, CNR1, OPRL1 | CNR2 1/4885CNR1 2/4885CRACR2A 714/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.